View Older Stories View More Recent Stories

Nov 5, 2019 07:00AM Intercept Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update
Oct 29, 2019 08:00AM Intercept to Announce Third Quarter 2019 Financial Results on November 5, 2019
Oct 28, 2019 08:00AM Intercept Announces New NASH and PBC Data to be Presented at The Liver Meeting® 2019
Sep 27, 2019 04:05PM Intercept Pharma (ICPT) Submits NDA to U.S. FDA for Obeticholic Acid in Patients with Fibrosis Due to NASH
Sep 27, 2019 04:05PM Intercept Submits New Drug Application to the U.S. FDA for Obeticholic Acid in Patients with Fibrosis Due to NASH
Sep 25, 2019 08:00AM Intercept to Present at Upcoming Investor Conference in October
Sep 11, 2019 08:00AM Intercept Launches NASHTRUTH.com, an Online Educational Resource for People with Advanced Fibrosis Due to NASH
Sep 9, 2019 08:00AM Intercept Appoints Lisa DeFrancesco as Vice President, Investor Relations
Aug 23, 2019 08:00AM Intercept to Present at Upcoming Investor Conferences in September
Aug 7, 2019 07:05AM Intercept Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update
Jul 31, 2019 08:00AM Intercept to Announce Second Quarter 2019 Financial Results on August 7, 2019
May 30, 2019 07:00AM Intercept to Present at Upcoming Investor Conferences in June
May 10, 2019 04:05PM Intercept to Present at Upcoming Investor Conferences in May
May 1, 2019 07:00AM Intercept to Announce First Quarter 2019 Financial Results on May 8, 2019
Apr 11, 2019 05:57AM Intercept Pharma (ICPT) Highlights Additional Positive Data from REGENERATE, the First Successful Phase 3 Study in NASH
Apr 11, 2019 02:00AM Intercept Reports Additional Positive Data from REGENERATE, the First Successful Phase 3 Study in NASH
Apr 4, 2019 07:00AM Intercept to Present Results from the First Successful Phase 3 Trial in Patients with Liver Fibrosis Due to NASH at the International Liver Congress™ 2019
Feb 19, 2019 07:03AM Intercept Pharma (ICPT) Announces Phase 3 REGENERATE Study in NASH Met Primary Endpoint
Feb 19, 2019 07:00AM Intercept Announces Positive Topline Results from Pivotal Phase 3 REGENERATE Study of Obeticholic Acid in Patients with Liver Fibrosis Due to NASH
Jan 7, 2019 07:07AM Intercept Pharma (ICPT) Announces NASH, PBC Program Updates
Jan 7, 2019 07:00AM Intercept Announces NASH and PBC Program Updates
Nov 5, 2018 07:00AM Intercept Announces New OCA Data to be Presented at The Liver Meeting® 2018
Apr 24, 2018 08:08AM Intercept Pharma (ICPT) Announces Nancy Miller-Rich to Board
Apr 24, 2018 08:00AM Intercept Pharmaceuticals Appoints Nancy Miller-Rich to Its Board of Directors
Apr 13, 2018 07:02AM Intercept (ICPT) Says Liver Biopsy Data from POISE Phase 3 Substudy Supports Obeticholic Acid's Ability to Reverse or Stabilize Fibrosis and Cirrhosis in PBC Patients
Apr 13, 2018 07:00AM Liver Biopsy Data from POISE Phase 3 Substudy Supports Obeticholic Acid’s Ability to Reverse or Stabilize Fibrosis and Cirrhosis in Primary Biliary Cholangitis (PBC) Patients
Mar 23, 2018 07:00AM Intercept Announces Multiple New Ocaliva® (obeticholic acid) Data Presentations at the International Liver Congress™ 2018
Feb 12, 2018 08:05AM Intercept Pharma (ICPT) Announces Phase 3 REVERSE Trial Evaluating OCA for Treatment of NASH Patients with Compensated Cirrhosis
Feb 12, 2018 08:00AM Intercept Announces Phase 3 REVERSE Trial Evaluating OCA for the Treatment of NASH Patients with Compensated Cirrhosis
Feb 1, 2018 09:47AM Intercept Pharma (ICPT) Confirms U.S. Prescribing Information for Ocaliva to Reinforce Appropriate Dosing in PBC Patients with Advanced Cirrhosis
Feb 1, 2018 09:46AM Intercept Announces Updated U.S. Prescribing Information for Ocaliva® (obeticholic acid) to Reinforce Appropriate Dosing in PBC Patients with Advanced Cirrhosis
Nov 27, 2017 07:05AM Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development
Oct 23, 2017 04:03PM Intercept Pharma (ICPT) Announces Positive Results from Phase 2 AESOP Trial Evaluating OCA for Treatment of PSC at AASLD's Liver Meeting
Oct 23, 2017 04:02PM Intercept Announces Positive Results from Phase 2 AESOP Trial Evaluating OCA for the Treatment of Patients with Primary Sclerosing Cholangitis at The Liver Meeting® 2017
Oct 11, 2017 07:51AM Intercept Pharma (ICPT) Says Data to be Presented at AASLD Meeting
Oct 11, 2017 07:44AM Intercept Announces Data to be Presented at The Liver Meeting® 2017
Feb 10, 2017 09:30AM Pre-Open Movers 02/10: (SHLD) (ICPT) (IMMU) Higher; (ONVO) (RSYS) (TCON) Lower (more...)
Jun 14, 2016 11:25AM Goldman M&A Basket in Focus After Predicting LinkedIn (LNKD); (TWTR) (BLUE) (TRIP), Others Added
May 31, 2016 12:09PM Streetinsider.com's Hot Lunchtime Reads 5/31: (AAPL) (MON) (VRX) (ICPT)
May 3, 2016 12:15PM Streetinsider.com's Hot Lunchtime Reads 5/3: (AAPL) (ICPT) (VRX) (TSLA)
Apr 7, 2016 09:32AM Pre-Open Stock Movers 04/07: (SUNE) (ICPT) (OLLI) (VRX) Higher; (ALDR) (TWTR) (YHOO) Lower (more...)
Apr 5, 2016 09:26AM Pre-Open Stock Movers 04/05: (VRX) (MRVL) (ICPT) Higher; (PSUN) (AGN) (NATI) Lower (more...)
Apr 4, 2016 11:23AM Intercept Pharma (ICPT) Ticks Higher Ahead of Expected FDA Briefing Docs on OCA in PBC
Dec 15, 2015 09:24AM Pre-Open Stock Movers 12/15: (KTOV) (LL) (VRX) Higher; (NEOT) (KMT) (ZOES) Lower (more...)
Oct 28, 2015 09:31AM Pre-Open Stock Movers 10/28: (CMI) (HOT) (CAB) (AIG) (AAPL) Higher; (MCUR) (AKAM) (ICPT) Lower (more...)
Feb 5, 2015 09:21AM Pre-Open Stock Movers 02/05: (HSP) (EOPN) (DATA) (TWTR) Higher; (QUIK) (ADEP) (IRBT) Lower (more...)
Jul 30, 2014 09:32AM Pre-Open Stock Movers 7/30: (GFIG) (TWTR) (NQ) Higher; (NTRI) (BWLD) (DWA) Lower (more...)
Jul 29, 2014 06:10PM After-Hours Stock Movers 7/29: (TWTR) (ZLTQ) (X) Higher; (NTRI) (BWLD) (DWA) Lower (more...)
Jul 1, 2014 09:34AM Pre-Open Stock Movers 7/1: (TSPT) (FOLD) (TWTR) Higher; (APP) (GEVA) (GNRC) Lower (more...)
May 29, 2014 09:29AM Pre-Open Stock Movers 5/29: (ASTC) (HSH) (PANW) Higher; (TLYS) (GMAN) (SOL) Lower (more...)
View More Recent Stories View Older Stories